- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06048770
A Study of RBI-4000 in Healthy Participants
March 6, 2024 updated by: Replicate Bioscience
A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of RBI-4000 in Healthy Volunteers
The primary purpose of the study is to evaluate the safety, reactogenicity, and immunogenicity of RBI-4000 administered at various dose levels via intramuscular injection and to determine the lowest dose of RBI-4000 necessary to elicit the rabies virus neutralizing antibody titer of equal or greater than (>=) 0.5 international unit per milliliter (IU/mL).
Study Overview
Status
Active, not recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
84
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Florida
-
Miami, Florida, United States, 33155
- Cordova Research Institute
-
-
Nebraska
-
Omaha, Nebraska, United States, 68134
- Velocity Clinical Research
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- Any gender participants between 18 and 45 years old, inclusive, at the time of the first vaccination.
- Body Mass Index >18 kilogram per square meter (Kg/m^2) and less than (<) 32 Kg/m^2.
Hematological/biochemical values within these parameters:
- White Blood Cells and differential, within the study designated laboratory normal range.
- Platelets = 125,000 - 500,000 cells per cubic millimeter (cells/mm^3)
- Hemoglobin within normal range of the study designated laboratory
- Liver function tests including alanine aminotransferase, aspartate aminotransferase, total bilirubin, and alkaline phosphatase within the study designated laboratory normal range.
- Female participants of non-childbearing potential or male participants with partners of childbearing potential may be enrolled in the study.
Female participants of childbearing potential may be enrolled in the study, if the participant
- has practiced adequate contraception for 30 days prior to vaccination, and
- has a negative pregnancy test on the day of vaccination (for female participants),
- has agreed to continue adequate contraception during the entire treatment period and for 2 months after completion of the vaccination series and agrees to not donate sperm (for male participants).
Exclusion Criteria:
- History of diagnosis with rabies exposure, infection or disease.
- History of rabies immunization (licensed or investigational) or human rabies immune globulin.
- Any confirmed or suspected immunosuppressive or immunodeficient condition based on medical history and physical examination.
- Family history of congenital or hereditary immunodeficiency.
- History of or current autoimmune disease.
- History of any reaction or hypersensitivity likely to be exacerbated by any components of commercially available rabies vaccines.
- Lymphoproliferative disorder or malignancy within previous 5 years (excluding effectively treated non-melanotic skin cancer, Ductal carcinoma in situ /Lobular carcinoma in situ (DCIS/LCIS).
- History of Type I hypersensitivity reactions to any beta-lactam antibiotics.
- Any acute or chronic, clinically significant disease, by history, physical examination, laboratory findings, subject personal report, and/or General Physician information.
- Any history of myocarditis and/or pericarditis.
- Administration of immunoglobulins and/or any blood products within the 3 months preceding the dose of study vaccine or planned administration during the study period.
- Chronic administration (defined as more than 14 days in total) of immunosuppressants or other immune-modifying drugs including steroids during the period within 6 months prior to the vaccine dose.
- Current allergy treatment with allergen immunotherapy with antigen injections, unless on maintenance schedule.
- Concomitant or planned administration of antimalarial drugs, including hydroxychloroquine within 30 days of vaccination.
- Current anti-tuberculosis prophylaxis or therapy.
- Pregnant or lactating female participant.
- Female participant planning to become pregnant or planning to discontinue contraceptive precautions.
- Participants with extensive tattoos covering deltoid region on both the arms that would preclude the assessment of local reactogenicity.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Sequential Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Multiple Ascending Dose (MAD) Cohorts, Cohort 1: RBI-4000 0.1 mcg
Participants will receive RBI-4000 0.1 micrograms (mcg) via intramuscular injection, once on Day 1 and Day 57.
|
RBI-4000 intramuscular injection.
|
Experimental: MAD Cohorts, Cohort 2: RBI-4000 1 mcg
Participants will receive RBI-4000 1 mcg via intramuscular injection, once on Day 1 and Day 57.
|
RBI-4000 intramuscular injection.
|
Experimental: MAD Cohorts, Cohort 3: RBI-4000 10 mcg
Participants will receive RBI-4000 10 mcg via intramuscular injection, single dose on Day 1.
|
RBI-4000 intramuscular injection.
|
Experimental: MAD Cohorts, Cohort 4: RBI-4000 10 mcg
Participants will receive RBI-4000 ,10 mcg via intramuscular injection, once on Day 1 and Day 57.
|
RBI-4000 intramuscular injection.
|
Active Comparator: Cohort 5: RabAvert 1 mL
Participants will receive RabAvert 1 milliliter (mL), intramuscular injection, once on Day 1 and Day 8.
|
RabAvert intramuscular injection.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Frequency of any Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
Time Frame: Day 1 up to 18 months
|
TEAEs and SAEs measured per the Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials (FDA 2007).
|
Day 1 up to 18 months
|
Immunogenicity of RBI-4000 Measured by Neutralizing Antibody Titers
Time Frame: Day 1 up to 18 months
|
Measured by neutralizing antibody titers >=0.5 IU/mL.
|
Day 1 up to 18 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Titer level of Rabies Virus Neutralizing Antibody
Time Frame: Day 1 and up to 18 months
|
Day 1 and up to 18 months
|
|
Durability of RBI-4000 Against Rabies Assessed by T-cell Levels
Time Frame: Day 1 and up to 18 months
|
Durability of RBI-4000 against rabies assessed by quantifying cytokine-producing T cells by ELISpot and flow cytometry.
|
Day 1 and up to 18 months
|
Rate of RBI-4000 Decay Over Time
Time Frame: Day 1 and up to 18 months
|
Day 1 and up to 18 months
|
|
Length of Time Above the Recognized Antibody Correlate of Protection Value
Time Frame: Day 1 and up to 18 months
|
Day 1 and up to 18 months
|
|
Lowest Dose of RBI-4000 that Provides Durable (greater than [>] 6 months) Coverage Above the Correlate of Protection
Time Frame: Day 1 and up to 18 months
|
Day 1 and up to 18 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
September 1, 2023
Primary Completion (Estimated)
April 14, 2025
Study Completion (Estimated)
April 14, 2025
Study Registration Dates
First Submitted
September 11, 2023
First Submitted That Met QC Criteria
September 20, 2023
First Posted (Actual)
September 21, 2023
Study Record Updates
Last Update Posted (Actual)
March 8, 2024
Last Update Submitted That Met QC Criteria
March 6, 2024
Last Verified
March 1, 2024
More Information
Terms related to this study
Other Study ID Numbers
- RBI-4000-101
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy Volunteers
-
AstraZenecaCompletedHealthy Elderly Volunteers | Healthy Young VolunteersUnited States
-
Syndax PharmaceuticalsCompletedHealthy Volunteers | Volunteers | Normal Volunteers | Human VolunteersUnited States
-
Syndax PharmaceuticalsCompletedHealthy Volunteers | Volunteers | Normal Volunteers | Human VolunteersUnited States
-
University Hospital, Clermont-FerrandUnite de Nutrition Humaine UMR 1019- INRAE; Unite MetaGenoPolis INRAE; France...CompletedHealthy Volunteers | Frail VolunteersFrance
-
Newcastle UniversityCompletedGI Glycaemic Index Healthy Volunteers | GL Glycaemic Load Healthy VolunteersUnited Kingdom
-
Galera Therapeutics, Inc.CelerionCompletedHealthy | Healthy VolunteersUnited States
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
PMV Pharmaceuticals, IncRecruitingHealthy VolunteersUnited States
Clinical Trials on RBI-4000
-
Rebiscan, Inc.Retina Foundation of the SouthwestWithdrawnStrabismus | AmblyopiaUnited States
-
Botanix PharmaceuticalsCompletedHyperhidrosisUnited States
-
Botanix PharmaceuticalsCompletedHyperhidrosisUnited States
-
Bioventus LLCMcMaster University; Clinical Advances Through Research and Information TranslationTerminatedTibial FracturesUnited States, Canada
-
Bioventus LLCTerminatedLumbar Degenerative Disc Disease
-
University of CalgaryBioventus LLC; Workers' Compensation Board, Alberta; Calgary Orthopaedic Research...Active, not recruitingFractures, Ununited | Nonunion of Fracture of Scaphoid BoneCanada
-
Hill-RomCompletedMotor Neuron Disease | Cystic Fibrosis | Airway Clearance ImpairmentUnited States
-
University Children's Hospital, ZurichCompletedMalignant Brain TumorsSwitzerland
-
University Children's Hospital, ZurichCompletedParkinson's Disease | Dystonia | Essential TremorSwitzerland
-
InSightecCompleted